688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- 8.43
- -0.22-2.54%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. News
Zhitong Hong Kong Stock Shareholder Equity Disclosure | December 11
Disclosure of shareholder equity in Hong Kong stocks | December 11.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong Stock Exchange Exploration | Healthy World Technology-B: LuX-Valve Plus TRAVEL II one-year clinical follow-up results to be released at the 2024 American Washington Congress of Cardiology through the catheter.
CH Energy Eng (03996) controlling shareholder received financial support for shareholding in A shares; following Takeda's FRUQUINTINIB (呋喹替尼/fruquintinib) sales exceeding 0.2 billion US dollars, Hutchmed (China) (00013) will receive the first milestone payment.
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Received Acceptance Notice by Nmpa for Abbreviated New Drug Application for Obeticholic Acid Tablets
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH): Obei cholic acid tablets for the treatment of primary biliary cholangitis pharmaceutical marketing application has been accepted.
On October 31, Bio-Thera Solutions (688505.SH) announced that its wholly-owned subsidiary, Taizhou Bio-Thera Solutions Pharmaceutical Co., Ltd., recently received the "Acceptance Notification" from the National Medical Products Administration regarding the application for domestic production pharmaceutical registration and market approval of obeticholic acid tablets (specifications: 5mg, 10mg) (referred to as "the drug") for the treatment of primary biliary cholangitis (PBC). This drug is a farnesoid X receptor (FXR) agonist, with FXR being a nuclear receptor highly expressed in the liver and intestines.
Fudan Zhangjiang Third Quarter Report 2024
Fudan-Zhangjiang Bio-Pharma's Q3 Profit Slides 25%
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (01349.HK): net income attributable to equity holders of the parent company in the first three quarters was 86.4686 million yuan
Gelonghui October 25th | Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co. Ltd. (01349.HK) announced that in the third quarter of 2024, revenue was 0.141 billion RMB, a decrease of 23.99% year-on-year; net income attributable to shareholders of the listed company was 15.9955 million RMB, a decrease of 25.44% year-on-year; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 10.8224 million RMB, a decrease of 34.74% year-on-year; earnings per share was 0.02 RMB. In the first three quarters of 2024, revenue was 0.549 billion RMB, a decrease of 22.47% year-on-year.
FUDANZHANGJIANG: THE THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Optimistic Investors Push Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349) Shares Up 51% But Growth Is Lacking
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (01349.HK) plans to hold a board of directors meeting on October 25th to approve the third quarter performance.
Glory Union October 14th | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that a board of directors meeting will be held on October 25, 2024 (Friday) to review and approve (including) the unaudited performance of the company and its subsidiaries for the third quarter ending on October 14, 2024 and its release.
FUDANZHANGJIANG: NOTICE OF BOARD MEETING
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Entered Into Agreement With Shanghai Pudong Development Bank
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (01349.HK) subscribed to 0.18 billion yuan structured deposit products
Oct. 8, Gelonhui| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that the company recently entered into a structural deposit product agreement with Bank of China, agreeing to subscribe for RMB 0.18 billion yuan of structural deposit products with the proceeds from the A-share public offering temporarily idle.
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Subscription of Structured Deposit Product Under Bank of China
China's assets continue to be popular! Japan's listed 500ETF rose by 115%, while the Hang Seng Index in Hong Kong once approached its recent high point.
What news stimulated the rise of semiconductor and pharmaceutical stocks in the Hong Kong stock market? What is the reason for the strong performance of petroleum stocks?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.'s (HKG:1349) Market Cap Surged HK$570m Last Week, Individual Investors Who Have a Lot Riding on the Company Were Rewarded
Fudan-Zhangjiang Bio-Pharma Enrolls First Patient in US Phase 2 Trial for Birthmark Treatment
shanghai fudan-zhangjiang bio-pharmaceutical co. ltd. (688505.SH): The first subject has been enrolled in the completion of the phase II clinical trial of injectable Hemoporfin for the treatment of fresh red nevus in the USA.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. announced on September 23 that the company's F0026 project, an injectable hemoporfin therapy for treating fresh red birthmarks, has successfully completed the first subject's enrollment in the phase II clinical trial in the USA. Hemoporfin is the world's first photodynamic drug for the treatment of fresh red birthmarks, integrating new drug targets, new compounds, and new indications into one. As a second-generation photosensitizer, hemoporfin has features such as stable compound structure and low phototoxicity. Its application in the treatment of fresh red birthmarks has been included in the People's Health Publishing House's textbook "Dermatology" (Ninth Edition).
No Data
